{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:44Z","timestamp":1762459784096},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Key Lab of Health Technology Assessment, Ministry of Health","award":["Not determined yet"],"award-info":[{"award-number":["Not determined yet"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12325-019-01056-8","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T18:02:36Z","timestamp":1566237756000},"page":"2881-2894","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"36","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"key":"1056_CR1","unstructured":"Nasdaq. FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN. 2017. \n                    http:\/\/www.cellectis.com\/en\/press\/fda-liftsclinical-hold-on-cellectis-phase-1-clinical-trials-with-ucart123-in-aml-and-bpdcn\n                    \n                  ."},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced. T cells Blood. 2012;119:12.","journal-title":"Blood"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:25.","journal-title":"Blood"},{"issue":"224","key":"1056_CR5","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med"},{"issue":"177","key":"1056_CR6","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.","journal-title":"Sci Transl Med"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119:17.","journal-title":"Blood"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2016-01-692764","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127:24.","journal-title":"Blood"},{"key":"1056_CR10","doi-asserted-by":"crossref","unstructured":"CS Sauter. Phase I trial of 19\u201328z chimeric antigen receptor modified T cells (19\u201328z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). ASCO. 2015","DOI":"10.1200\/jco.2015.33.15_suppl.8515"},{"issue":"95","key":"1056_CR11","first-page":"95ra73","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Leukemia. 2011;3(95):95ra73.","journal-title":"Leukemia"},{"issue":"1","key":"1056_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","journal-title":"Mol Ther"},{"issue":"11","key":"1056_CR13","doi-asserted-by":"publisher","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","volume":"4","author":"H Dai","year":"2015","unstructured":"Dai H, Zhang W, Li X, Han Q, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. OncoImmunology. 2015;4(11):e1027469.","journal-title":"OncoImmunology"},{"key":"1056_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig. 2016;126:6.","journal-title":"J Clin Investig"},{"issue":"355","key":"1056_CR15","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+\u2009and CD4+\u2009CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","journal-title":"Sci Transl Med"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"key":"1056_CR17","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi L-A, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010\u201320.","journal-title":"J Clin Oncol"},{"key":"1056_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415","author":"D Porter","year":"2015","unstructured":"Porter D, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aac5415\n                    \n                  .","journal-title":"Sci Transl Med"},{"key":"1056_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.tps3095","author":"SI Park","year":"2017","unstructured":"Park SI, Serody JS, Shea TC, Grover NS, Ivanova A, Morrison K. A phase 1b\/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2017. \n                    https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.tps3095\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1056_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"1056_CR21","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1056_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"D. T. Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664\u201379.","journal-title":"Cancer Discovery"},{"key":"1056_CR23","volume-title":"Systematic reviews in health care: meta-analysis in context","year":"2001","unstructured":"Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ; 2001."},{"key":"1056_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0140-6736(93)93004-K","volume":"341","author":"LA Stewart","year":"1993","unstructured":"Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 1993;341:418\u201322.","journal-title":"Lancet"},{"issue":"4","key":"1056_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccr.2013.02.005","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase and is decreased in pancreatic cancer. Cancer Cell. 2013;23(4):464\u201376.","journal-title":"Cancer Cell"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01056-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01056-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T23:16:11Z","timestamp":1597706171000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01056-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01056-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}